<DOC>
	<DOCNO>NCT02663518</DOCNO>
	<brief_summary>Multicenter , open-label , Phase 1a/1b trial TTI-621 subject relapse refractory hematologic malignancy .</brief_summary>
	<brief_title>A Trial TTI-621 Patients With Hematologic Malignancies</brief_title>
	<detailed_description>This trial TTI-621 subject relapse refractory hematologic malignancy conduct 2 part . In dose Escalation Phase , subject lymphoma enrol sequential dose cohort receive TTI-621 characterize safety , tolerability , pharmacokinetics , maximum-tolerated dose ( MTD ) . In Expansion Phase , subject variety hematologic malignancy treat optimal dose define safety characterize efficacy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Histologically document advanced lymphoma ( escalation ) advance hematologic malignancy ( expansion ) evaluable disease . 2 . Adequate hematologic status 3 . Relapsed refractory disease least 1 prior systemic treatment primary malignancy candidate curative treatment . 4 . Adequate coagulation function 5 . Adequate hepatic function 6 . Adequate renal function 1 . Known central nervous system disease involvement . 2 . Allogeneic transplant within 100 day prior planned start treatment subject active graftvshost disease exception Grade 1 skin involvement . 3 . History hemolytic anemia bleed diathesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>